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A fall 2016 outbreak of enterovirus D68 infection in St. Lou-
is, Missouri, USA, had less effect than a fall 2014 outbreak 
on hospital census, intensive care unit census, and hospi-
talization for a diagnosis of respiratory illness. Without on-
going surveillance and specific testing, these cases might 
have been missed. 
The largest known outbreak of enterovirus D68 (EV-D68) occurred in the United States in 2014 (1). Se-
vere respiratory illnesses increased in fall of 2014, cor-
responding to a period when EV-D68 was present in the 
community, at St. Louis Children’s Hospital (St. Louis, 
Missouri, USA) and elsewhere in the United States (1,2). 
Multiple reports suggested that the predominant virus 
was from clade B1, although some viruses from clades 
B2 were also detected (3–5). During 2015, there were few 
reports of EV-D68 circulating in the United States (6); 
however, in 2016, EV-D68 reappeared in multiple US lo-
cations (New York, Colorado); virus sequences suggested 
that the predominant virus was from clade B3 (4,7). We 
also documented EV-D68 activity in St. Louis in 2016. 
Sequencing of viruses from 2 patients tested in the St. 
Louis Children’s Hospital virology laboratory revealed 
clade B3 with 99% identity to the clade B3 virus from 
New York (8). Our goal with this study was to determine 
if the 2016 outbreak had caused an increase in hospital 
census or increase in patients admitted with respiratory 
diagnosis, as was seen during the 2014 outbreak.
During August 7, 2016, through December 16, 2016, 
we used a previously described EV-D68–specific PCR to 
test 5%–10% of enterovirus/rhinovirus–positive samples 
submitted each week to the St. Louis Children’s Hospi-
tal diagnostic virology laboratory. The samples had been 
obtained from patients seen at the hospital’s emergency 
department or clinics or admitted to the inpatient units 
and had been routinely tested by a FilmArray Respiratory 
Panel (BioFire, Salt Lake City, UT, USA) (9). Samples 
were selected by laboratory staff without regard to patient 
characteristics and were deidentified before EV-D68 test-
ing. We obtained inpatient and intensive care unit (ICU) 
census data for all patients (not limited to those with a 
respiratory diagnosis) and discharge diagnoses for hos-
pitalized patients from the hospital’s Health Information 
Management System, an administrative database, for 
2013–2016. 
Discharge diagnoses were categorized as respiratory 
or nonrespiratory. A respiratory diagnosis was defined as 
any principal diagnosis referring to disease processes of the 
respiratory tract (e.g., asthma exacerbation, bronchiolitis, 
respiratory distress, respiratory failure, pneumonia). We 
used the Pearson χ2 test of independence to compare the 
frequency distribution of patients with a respiratory diag-
nosis in 2014 and 2016 with frequency of those in 2013 
and 2015 combined. All analyses were done with SAS/
STAT software version 9.4 for Windows (SAS Institute, 
Cary, NC, USA). The Washington University Institutional 
Review Board determined that this project did not meet the 
definition of human subject research and, as such, was not 
subject to institutional review board review.
During August 7–November 5, 2016, we tested a to-
tal of 4,190 samples by using the viral respiratory panel; 
1,058 (25%) were positive for rhinovirus/enterovirus. 
Further testing of 179 samples positive for rhinovirus/
enterovirus revealed that 19 (11%) were positive for EV-
D68 (online Technical Appendix Figure, panel A, https://
wwwnc.cdc.gov/EID/article/24/11/18-0397-Techapp1.
pdf). During November 6–26, 2016, we tested 47 rhino-
virus/enterovirus–positive samples, and 4/47 (9%) were 
positive for EV-D68. During November 27–December 
10, 2016, we tested 33 rhinovirus/enterovirus–positive 
samples, and none were positive for EV-D68. We did not 
include EV-D68 testing data from November 6–Decem-
ber 10, 2016, in the online Technical Appendix Figure 
because of the difficulty in obtaining discharge diagnosis 
data (changes in registration systems affected data collec-
tion during that period). 
In contrast to the experience in 2014, overall inpatient 
or ICU census did not increase during this outbreak except 
for a 1–2 week period in October (online Technical Ap-
pendix Figure, panels B–D). During August 7–November 
5, 2014, the number and percentage of patients hospital-
ized with a respiratory diagnosis increased significantly 
(852/5,894, 14%) compared with the corresponding pe-
riods in 2013 and 2015 combined (1,156/10,958, 11%; 
p<0.0001). This increase in patients hospitalized with re-
spiratory diagnoses in 2014 overlapped with the increase 
in EV-D68 activity in our hospital. In 2014, we tested 572 
rhinovirus/enterovirus–positive specimens from August 3, 
2104–October 31, 2014, and 159 (28%) were positive for 
EV-D68 (2). In contrast, the number and percentage of pa-
tients admitted with a respiratory diagnosis during August 
7–November 5, 2016, decreased significantly (483/5,304, 
9%) compared with the corresponding periods in 2013 and 
2015 combined (p = 0.004).
The overall effects of the 2016 outbreak seem to have 
been less than those of the 2014 outbreak. The epidemiologic 
data from our hospital, which has a broad catchment area in 
the central United States, confirm that the period of EV-D68 
activity in 2016 had less effect on hospital census, ICU cen-
sus, and hospitalization for respiratory diagnosis than that 
in 2014. Although the measured parameters are relatively 
crude, we found no changes in data collection procedures 
that explain the observed differences, suggesting that the dif-
ferences are the result of lower levels of EV-D68 circulation 
in the population in 2016. Our study suggests that surveil-
lance using specific testing is needed to detect EV-D68 ac-
tivity, which would have been missed if we had monitored 
only for increases in patients with respiratory diagnoses or 
hospital census.
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Among students with influenza-like illness at a Pennsyl-
vania college student health center during 2016–2017, 44 
(15%) of 288 with respiratory specimens tested positive 
for human adenovirus (HAdV). HAdV-3, -7, and -4 pre-
dominated, and types clustered temporally. HAdV infection 
should be considered among college students with acute 
respiratory illness.
Human adenoviruses (HAdVs) cause a range of clini-cal manifestations, most commonly acute respiratory 
illness (ARI), gastroenteritis, and conjunctivitis. Seven 
HAdV species (A–G) and >80 types are known to cause 
human infection, and certain HAdV types are associated 
with particular tissue tropisms and clinical syndromes (1). 
Outbreaks of HAdV infection occur in a variety of settings, 
including schools, long-term care facilities, military recruit 
training facilities, and the civilian community (2–4). The 
substantial impact of HAdV ARI among US military re-
cruits drove development of the first live oral vaccine for 
HAdV types 4 and 7 for military use. After vaccine intro-
duction in 1971, and again after reintroduction in 2011, 
dramatic declines were documented in respiratory illness 
among recruits (5). Currently, the HAdV vaccine for types 
4 and 7 is licensed in the United States for use in military 
personnel 17–50 years of age and is administered routinely 
at all US basic military training sites (5). However, despite 
some similarities between military recruits and civilian col-
lege students, including age and sharing of residences, little 
is known about the contribution of HAdV to respiratory ill-
ness in college students.
The Pennsylvania Department of Health (PDH) con-
ducts surveillance for influenza-like illness (ILI), defined 
as fever (temperature >100°F [>37.8°C]) plus cough or 
sore throat without a known cause other than influenza, 
at participating outpatient healthcare facilities throughout 
the state. Basic demographic information is recorded, and 
from a convenience sample of cases, a nasopharyngeal 
swab specimen is collected. These specimens are tested by 
the PDH Bureau of Laboratories using Centers for Disease 
Control and Prevention (CDC) real-time reverse transcrip-
tion PCR for influenza A and B, HAdV, respiratory syncy-
tial virus, human metapneumovirus, rhinovirus, and parain-
fluenza virus types 1–3.
We describe HAdV types associated with ILI among 
students who sought care at a student health center (SHC) 
on a large college campus during August 28, 2016–August 
26, 2017. Specimens identified as HAdV-positive among 
students with ILI at the SHC were sent to CDC to deter-
mine HAdV species and type. Molecular typing was per-
formed by PCR and sequencing of the hexon hypervariable 
regions 1–6 (6).
During the study period, 1,149 ILI cases were report-
ed from the SHC; for 288 (25%), a nasopharyngeal swab 
specimen was tested for respiratory viruses (Figure, panel 
A). Of these, 44 (15%) specimens were positive for HAdV. 
Three HAdV species and 4 HAdV types were detected: 
HAdV-3 and HAdV-7 of species HAdV-B in 21 (48%) and 
16 (36%), respectively; HAdV-4 of species HAdV-E in 5 
(11%); and HAdV-1 of species HAdV-C in 2 (5%). The 
median age of HAdV-positive students was 19 years (range 
18–27 years), and 31 (70%) were male. Among HAdV-
positive specimens, rhinovirus was co-detected in 4 and 
parainfluenza virus type 2 in 1. 
HAdV-3 was identified during September–December; 
no additional HAdV-3 was identified after the 4-week win-
ter break. HAdV-7 and -4 were first detected in December, 
before winter break, then throughout the spring; HAdV-7 
was the most commonly detected type during this period 
(Figure, panel B).
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Technical Appendix Figure. Numbers of samples tested for enterovirus D68 (A), number of patients with 
respiratory diagnosis (B), and inpatient (C) and intensive care unit (D) daily census for patients admitted 
for any illness to St. Louis Children’s Hospital, St. Louis, Missouri, USA, 2013–2016. Discharge 
diagnoses were categorized as respiratory or nonrespiratory. Respiratory diagnoses were defined as any 
principal diagnosis referring to disease process of the respiratory tract. 
